Patient Engagement in Gene and Cell Therapy: What is Different?

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Cell and gene therapy (CGT) offers new hope for patients. There are essential differences between the patient, product and system journeys for CGT vs. conventional medicines. These unique challenges present across the drug development continuum – from early stage development programs to approval and launch activities, to long term care and treatment, to strategies that support access to these potentially transformative treatments.

How does industry engage patient communities in mutually beneficial ways to ensure success of CGT? What roles do industry, patients and patient organizations each play to address needs? These questions and more will be discussed by the session panelists.
President & CEO
VOZ Advisors
Vice President, Public Affairs and Stakeholder Engagement
Orchard Therapeutics
Consultant and Patient Advocate
Project Alive